Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 17Terminated 3Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 10Gynecologic 5Genitourinary 4Endocrine 4NET 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 75Cyclophosphamide 68Cytarabine 59fludarabine 49Azacitidine 44Specimen Handling 36fludarabine phosphate 35Rituximab 34Biopsy 30Methotrexate 28ibrutinib 27Daunorubicin 25Dexamethasone 24Vincristine 23obinutuzumab 21Etoposide 21Decitabine 21acalabrutinib 19Tacrolimus 19Dasatinib 19blinatumomab 18Melphalan 18Prednisone 16Mycophenolic Acid 16Granulocyte Colony-Stimulating Factor 16Busulfan 16Whole-Body Irradiation 15Doxorubicin 15Injections 14pegaspargase 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Everolimus × Other hematologic neoplasm × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
45 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡